NEW YORK, March 02, 2017 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Aratana Therapeutics, Inc. securities (NASDAQ:PETX) from March 16, 2015 through February 3, 2017, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Aratana investors under the federal securities laws.
To join the Aratana class action, go to http://rosenlegal.com/cases-1049.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Aratana did not have manufacturing contracts in place sufficient to support manufacturing of ENTYCE at a commercial scale; (2) consequently, ENTYCE was not likely to be commercially available until late 2017; (3) accordingly, Aratana had misled investors with respect to the likely timeline for a commercial launch of ENTYCE; and (4) as a result, Aratana’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 7, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1049.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com


Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 



